COVID-19患者体内的抗核抗体反映了潜在的疾病：在系统性硬化（CDK9）和恶性肿瘤（RNF20，RCC1，TRIP13）中发现了新的自身抗体。
Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13).
发表日期：2023 Feb 02
作者：
Xavier Bossuyt, Jean-Baptiste Vulsteke, Jan Van Elslande, Lise Boon, Greet Wuyts, Silke Willebrords, Glynis Frans, Nick Geukens, Sebastien Carpentier, Sabine Tejpar, Hans Wildiers, Daniel Blockmans, Ellen De Langhe, Pieter Vermeersch, Rita Derua
来源：
AUTOIMMUNITY REVIEWS
摘要：
COVID-19中抗核抗体（ANA）高流行率已被暗示，但目标抗原的性质尚不清楚。我们通过间接免疫荧光法研究了229名COVID-19患者的ANA。使用免疫沉淀（IP）结合液相色谱-质谱（MS）确定高滴度ANA（≥1:320）的靶抗原。在COVID-19患者中，发现14人（6%）具有高滴度ANA（≥1:320）。在具有高滴度ANA的14个COVID-19病例中，有6个患有潜在的自身免疫性疾病，5个患有肿瘤。IP-MS揭示了与自身免疫性疾病相关的已知靶抗原以及新的自身抗原，包括系统性硬化症中的CDK9和肿瘤中的RNF20，RCC1和TRIP13。通过IP-Western blotting证实了这些新的自身抗原。总之，深入分析高滴度ANA的靶标揭示了系统性硬化症和恶性疾病中的新自身抗原。版权所有©2023 Elsevier B.V.出版。
A high prevalence of antinuclear antibodies (ANA) in COVID-19 has been insinuated, but the nature of the target antigens is poorly understood. We studied ANA by indirect immunofluorescence in 229 individuals with COVID-19. The target antigens of high titer ANA (≥1:320) were determined by immunoprecipitation (IP) combined with liquid-chromatography-mass spectrometry (MS). High titer ANA (≥1:320) were found in 14 (6%) of the individuals with COVID-19. Of the 14 COVID-19 cases with high titer ANA, 6 had an underlying autoimmune disease and 5 a malignancy. IP-MS revealed known target antigens associated with autoimmune disease as well as novel autoantigens, including CDK9 (in systemic sclerosis) and RNF20, RCC1 and TRIP13 (in malignancy). The novel autoantigens were confirmed by IP-Western blotting. In conclusion, in depth analysis of the targets of high titer ANA revealed novel autoantigens in systemic sclerosis and in malignant disease.Copyright © 2023. Published by Elsevier B.V.